Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


P&G azimilide arrythmia trial recruiting 5,900 patients with low LVEF, low heart rate variability.

Executive Summary

P&G AZIMILIDE ARRHYTHMIA TRIAL ENROLLING 5,900 PATIENTS at 600 sites worldwide, John Camm, MD, St. George's Hospital Medical School (London), said at a Procter & Gamble-sponsored symposium on antiarrhythmic drugs Aug. 26 at the European Society of Cardiology meeting in Stockholm. The "ALIVE" trial (Azimilide Post-Infarct Survival Evaluation) will study the effect of oral 75 mg and 100 mg azimilide dihydrochloride vs. placebo on recent post-myocardial infarction patients with a left ventricular ejection fractions ranging between 15%-35% and low heart rate variability, Camm stated.



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts